Clinical trial NCT01675947: Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy
Official title: Multi-Center, Randomized, Single Masked Phase 2 Study of Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Geographic Atrophy
Lead sponsor: National Eye Institute (NEI)
Sponsor class: NIH
Collaborators: name: The Emmes Company, LLC
name: Santen Inc.
First posted: 2012-08-30
Enrollment: 52
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will seek to enroll 50 persons who have central or non-central geographic atrophy (GA) associated with age-related macular degeneration (AMD). GA in treated eye must be between 0.75 disk areas (DA) and 8 DA. Eligible participants will be randomly chosen to receive one of the following treatments in the study eye:

1. A 20 μL (440 μg) intravitreal (IVT) injection of sirolimus, or
2. A sham treatment (subconjunctival injection of lidocaine) Participants with two (2) eligible eyes will have one eye randomly assigned to receive intravitreal sirolimus and no sham in the fellow eye.

The first injection will begin at Day 0, which may occur on the date of screening/enrollment or up to two weeks following screening/enrollment visit, and every month thereafter. The visit schedule is as follows:

1. A clinical evaluation, including safety measures, will occur monthly.
2. Vision will be measured at the screening/enrollment visit and at 2, 3, 6, 9, 12, 18 and 24 months after the first injection has occurred.
3. Fundus autofluorescence will occur at screening/enrollment and at 2, 6, 12, 18 and 24 months after the first injection has occurred.
4. Fundus color photography and optical coherence tomography will occur at screening/enrollment and at 6, 12, 18 and 24 months after the first injection has occurred.

The primary goal is to evaluate whether the persons receiving the sirolimus injections show a slower worsening of geographic atrophy compared to the persons receiving the sham injections. A secondary goal is to evaluate the impact of sirolimus on vision compared to the sham.

NOTE: As of May 30, 2014, study injections were discontinued due to safety concerns. No further enrollments will occur and follow-up will continue on all active study participants on a quarterly basis. That is, on visits coinciding with 3 month intervals from date of enrollment.


Eligibility criteria: Inclusion Criteria:

* Age 55 years of age or older. Prior participation in the Age-Related Eye Disease Study 2 (AREDS2) is not required.
* Participant must understand and sign the protocol's informed consent document.
* Participant must have central or non-central geographic atrophy (GA) in at least one eye. GA should be at least 0.75 disk areas (DA) in size but no more than 8 disk areas (DA); approximately 2.54 mm2 is 1 DA. GA is defined as one or more well-defined, usually more or less circular patches of partial or complete de-pigmentation of the retinal pigment epithelium (RPE), typically with exposure of underlying choroidal blood vessels. Even if much of the RPE appears to be preserved and large choroidal vessels are not visible, a round patch of RPE partial de-pigmentation may still be classified as early GA.
* Participant must have a steady fixation in the study eye in the foveal or parafoveal area and media clear enough for good quality photographs.
* Participant must have visual acuity between 20/25 and 20/200 in the study eye.
* Female participants must be post-menopausal.
* Male participants with female partners capable of conceiving children will be required to use contraception during the study and for four months after their last sirolimus injection.

Exclusion Criteria:

* Participant is in another investigational study other than AREDS2 and actively receiving study therapy for geographic atrophy or choroidal neovascularization (CNV).
* Participant is unable to comply with study procedures or follow-up visits.
* Participant has evidence of ocular disease other than AMD in either eye that may confound the outcome of the study (e.g., glaucoma, diabetic retinopathy with 10 or more hemorrhages or microaneurysms, uveitis, pseudovitelliform macular degeneration, moderate/severe myopia).
* Participant has received treatment for AMD, such as macular laser, photodynamic therapy (PDT) or anti-vascular endothelial growth factor (anti-VEGF) therapy injection. Or the participant received an IVT injection of any agent (e.g., triamcinolone) other than an anti-VEGF agent within the last four months prior to study enrollment. Vitamin supplementation for AMD is not considered an exclusionary criterion.
* Participant has had a vitrectomy.
* Participant is expected to need ocular surgery during the course of the trial.
* Participant has undergone lens removal in the last three months or Yttrium Aluminium Garnet (YAG) laser capsulotomy within the last month.
* Participant is on chemotherapy.
* Participant is on immunosuppressive medication or is immunosuppressed.
* Participant is on ocular or systemic medications known to be toxic to the lens, retina or optic nerve.
* Participant with a history of malignancy that would compromise the 2-year study survival.
* Participant with a history of ocular herpes simplex virus (HSV).
* A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control).
* History of cancer (other than a non-melanoma skin cancer) diagnosed within the past five years that could be worsened by immunosuppression. (The risk of immunosuppression must be determined by an oncology consultation prior to enrollment.)
* Ocular or periocular inflammation or infection in either eye.
* Presence of active or inactive toxoplasmosis in the study eye.

Primary outcomes:
measure: Rate of change in area of geographic atrophy
timeFrame: Every 6 months after enrollment for 2 years
Secondary outcomes:
measure: Change in best-corrected visual acuity
timeFrame: Every 6 months after enrollment for 2 years
Other outcomes:
measure: Number and severity of systemic and ocular toxicities, adverse events and infections
timeFrame: Monthly for 2 years
Locations:
city: Loma Linda
country: United States
facility: Loma Linda University
state: California
city: Sacramento
country: United States
facility: University of California, Davis
state: California
city: Jacksonville
country: United States
facility: University of Florida HSC
state: Florida
city: Atlanta
country: United States
facility: Emory University
state: Georgia
city: Chicago
country: United States
facility: University of Illinois
state: Illinois
city: Baltimore
country: United States
facility: Elman Retina Group
state: Maryland
city: Grand Rapids
country: United States
facility: Vision Research Foundation
state: Michigan
city: Charlotte
country: United States
facility: Charlotte Eye Ear Nose & Throat Associates
state: North Carolina
city: Philadelphia
country: United States
facility: Scheie Eye Institute, University of Pennsylvania
state: Pennsylvania
city: West Columbia
country: United States
facility: Palmetto Retina Center
state: South Carolina
city: Knoxville
country: United States
facility: Southeastern Retina Associates, P.C.
state: Tennessee
city: Dallas
country: United States
facility: Texas Retina Associates
state: Texas
city: Madison
country: United States
facility: University of Wisconsin
state: Wisconsin
Study officials:
affiliation: National Eye Institute (NEI)
name: Emily Y Chew, MD
role: STUDY_CHAIR
References: